CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

Inclusion Criteria: * Karnofsky Performance Score (KPS) ≥ 70% * Estimated Life Expectancy of at least 3 months * Documented histological or cytological diagnosis of renal cell carcinoma with a clear-cell component. * Measurable Disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the Investigator * Must have received at least two prior lines of systemic therapy, including at least one VEGF TKI (e.g., sunitinib, sorafenib, pazopanib, cabozantinib) a) Radiographic progression of mRCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to Cycle 1 Day 1 (C1D1). * Prior treatment with other anti-cancer therapies including cytokines, monoclonal antibodies, immunotherapies, and cytotoxic chemotherapy is allowed Exclusion Criteria: * Prior treatment with mammalian target of rapamycin (mTOR) inhibitors (everolimus or temsirolimus) or CB-839 * Receipt of any anticancer therapy within the following windows before randomization: * TKI therapy within 2 weeks or 5 half-lives, whichever is longer * Any type of anti-cancer antibody within 4 weeks * Cytotoxic chemotherapy within 4 weeks * Investigational therapy within 4 weeks or 5 half-lives, whichever is longer * Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Patients with clinically relevant ongoing complications from prior radiation therapy a…